Total Voting Rights

RNS Number : 9445B

Hikma Pharmaceuticals Plc

04 February 2020

 

Hikma Pharmaceuticals PLC

Total Voting Rights and Capital

LONDON, 4 February 2020 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 31 January 2020, its share capital consists of 242,329,031 ordinary shares with voting rights. There are nil shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's DTR's.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

 

END

 

 

TVREALALEEKEEFA